90 related articles for article (PubMed ID: 14578687)
1. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.
Armstrong DK; Blessing JA; Look KY; Schilder R; Nunez ER
Invest New Drugs; 2003 Aug; 21(3):373-7. PubMed ID: 14578687
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.
Armstrong DK; Blessing JA; Rader J; Sorosky JI;
Invest New Drugs; 2003 Nov; 21(4):453-7. PubMed ID: 14586213
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.
Clamp AR; Blackhall FH; Vasey P; Soukop M; Coleman R; Halbert G; Robson L; Jayson GC;
Br J Cancer; 2003 Oct; 89(7):1152-4. PubMed ID: 14520436
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
Herzog TJ; Sill MW; Walker JL; O'Malley D; Shahin M; DeGeest K; Weiner SA; Mutch D; DeBernardo RL; Lentz SS
Gynecol Oncol; 2011 Mar; 120(3):454-8. PubMed ID: 21168198
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.
Morgan RJ; Leong L; Chow W; Gandara D; Frankel P; Garcia A; Lenz HJ; Doroshow JH
Invest New Drugs; 2012 Apr; 30(2):723-8. PubMed ID: 20936324
[TBL] [Abstract][Full Text] [Related]
9. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
Tozer RG; Burdette-Radoux S; Berlanger K; Davis ML; Lohmann RC; Rusthoven JR; Wainman N; Zee B; Seymour L;
Invest New Drugs; 2002 Nov; 20(4):407-12. PubMed ID: 12448658
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of bryostatin-1 in metastatic melanoma.
Bedikian AY; Plager C; Stewart JR; O'Brian CA; Herdman SK; Ross M; Papadopoulos N; Eton O; Ellerhorst J; Smith T
Melanoma Res; 2001 Apr; 11(2):183-8. PubMed ID: 11333129
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of bryostatin 1 in metastatic malignant melanoma.
Propper DJ; Macaulay V; O'Byrne KJ; Braybrooke JP; Wilner SM; Ganesan TS; Talbot DC; Harris AL
Br J Cancer; 1998 Nov; 78(10):1337-41. PubMed ID: 9823975
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
16. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
